The Division is actively conducting various research projects under the oversight of its Cardiovascular Research Unit (CRU), directed by Dr. Ray Matthews (Medical Director) and Dr. Leonardo Clavijo (Associate Director). Areas of research include carotid artery disease, coronary artery disease, ischemic heart disease and myocardial infarction, congenital heart disease, heart failure and electrophysiological heart disorders. The CRU specializes in cutting-edge technology for pacemaker and cardiac devices and oversees all investigator-initiated, federal, foundation and industry-sponsored studies in the Division of Cardiovascular Medicine, working closely with the USC Clinical Trials Office (CTO), Department of Contracts and Grants (DCG) and the USC Health Sciences Campus Institutional Review Board (IRB). The Division also has an active technology development program and has worked closely with the USC Stevens Institute for Innovation and outside entities to develop new technology and use of modern communication modalities to diagnose cardiovascular disease and fully engage patients and patients’ families and caregivers. Currently, the Division has 48 federal, foundation and industry sponsored protocols and 10 investigator-initiated protocols.
David M. Shavelle, MD
Dr. Shavelle is involved in several research studies: he is a Principal Investigator and is on the National Steering Committee for the post FDA approval CardioMEMS study that is evaluating the use of the CardioMEMS HF device in patients with class III NYHA heart failure. He is a Co-Investigator for the PARACHUTE IV clinical trial that is evaluating the use of a novel device placed within the left ventricular apex to improve cardiac function in patients with class III NYHA heart failure and participates in multicenter registry evaluating the use of the AngioVac system. He is an advisor to Emergency Medical Services (EMS) of Los Angeles County and is involved in several ongoing research projects related to the treatment of out of hospital cardiac arrest and ST elevation myocardial infarction.
Ray V. Matthews, MD
Dr. Ray Matthews’ research interests include high risk percutaneous coronary intervention and the devices that provide hemodynamic support during these procedures. He is the Principal Investigator for the Shield II study, which is a multicenter randomized trial between the HeartMate PHP and the IMPELLA® 2.5 for hemodynamic support during the performance of high risk coronary intervention. Dr. Matthews has lectured nationally and internationally on this topic.
Catheter interventions for structural heart disease are also an interest of Dr. Matthews. He serves as Co-Principal Investigator for the PORTICO study. This is a randomized trial between commercially available transcatheter aortic valves and the PORTICO transcatheter valve in patients at high risk for surgical aortic valve replacement. Dr. Matthews is a physician educator and proctor for the performance of transcatheter aortic valve replacement (TAVR) and has lectured nationally and internationally on the topic. Dr. Matthews and USC have also been selected to be part of an early experimental trial of transcatheter mitral valve replacement scheduled to begin in 2017.
Rahul N. Doshi, MD
Dr. Doshi, Director of Electrophysiology, is Principal Investigator and on the Steering Committee for the Leadless II NANOSTIM study, which examines a revolutionary pacemaker that is smaller than conventional pacemakers and does not require wire leads. He is Principal Investigator and Steering Committee member for EMPOWER study, another leadless pacemaker that can also communicate with an Implantable Defibrillator. He remains active in the investigation of catheter ablation for atrial fibrillation (AF), participating in multiple trials and leading the research in novel approaches for this disease, including the AMAZE trial and Vein of Marshall Study looking at left atrial appendage (LAA) ligation and ethanol ablation for AF. Dr. Doshi is actively involved in all forms of LAA occlusion or exclusion, participating in several different trials. He is Principal Investigator for the AMULET trial and is one of a handful of physicians in the U.S. that performs this procedure paired with a curative catheter ablation for AF. Dr. Doshi also is actively involved in heart failure therapy and is leading the investigation of the relationship of hemodynamic sensors and arrhythmia onset and burden. Currently he is involved with over a dozen different clinical trials encompassing all areas of implantable device and ablation therapy.
Leonardo C. Clavijo, MD, PhD
Dr. Clavijo is Principal Investigator of the Same Day Discharge study, an investigator-initiated study sponsored by Abbott. The purpose of this study is to compare the strategies, outcomes and complication rates of early (same day) versus delayed (day after the procedure) hospital discharge in patients undergoing single and multi-vessel stenting of types A, B and C lesions. Dr. Clavijo is also Principal Investigator and author for ASA/Plavix and STT-Clips, \ studies that examine clot prevention and are high on-treatment platelet reactivity in patients with critical limb ischemia.
Leslie A. Saxon, MD
Dr. Saxon founded the USC Center for Body Computing (CBC) in 2006. The Center helps extend the reach and depth of CVTI research by working with outside entities as diverse as Apple, VSP Global, Qualcomm, Proteus Digital Health, St. Jude Medical, the United States Army Research Lab and the NFL. Collaborating with the CVTI and the Keck School of Medicine of USC, the CBC is conducting feasibility studies with state-of-the-art devices that can wirelessly monitor patients remotely, in addition to creating social networks, mobile apps and virtual care providers to help extend the reach of the CVTI cardiovascular specialists to our patient populations locally, and one day, nationally.